Live feed20:30:00·36dPRReleasevia QuantisnowImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027ByQuantisnow·Wall Street's wire, on your screen.IBRX· ImmunityBio Inc.Health Care
